ArticleJournal of surgical case reports2025
Esophageal pleomorphic rhabdomyosarcoma: a rare high-grade sarcoma managed with upfront resection.
Article in Journal of surgical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary esophageal sarcomas are exceedingly rare, with a subtype of pleomorphic rhabdomyosarcoma (PRMS) as exceptionally uncommon. We present the case of a healthy 58-year-old male with significant smoking history with 3 months of progressive dysphagia and 30 lb weight loss. Endoscopy revealed a large esophageal mass with biopsy demonstrating a high-grade malignant neoplasm with spindle cell features, favoring sarcoma. Staging workup confirmed a localized intraluminal tumor without distant metastasis. Given the progressive nature of the mass and near-complete obstruction, the patient underwent immediate esophagectomy. Final pathology demonstrated an 8.7 cm high grade PRMS involving the mucosa and submucosa without lymph node involvement, Stage IIIA (pT2N0M0), based on the American Joint Commission on Cancer (AJCC) criteria. This case underscores the importance of distinguishing sarcomas from esophageal carcinomas and recognizing early surgery as the cornerstone of management in localized PRMS given its limited responsiveness to chemoradiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.